Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Magrolimab Clear all
Terminated Phase 1Phase 2 Interventional Results available

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

NCT04435691
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Magrolimab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

NCT06046482
View directory record Official record
Conditions
Head Neck, Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, Magrolimab, cetuximab, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

NCT02953782
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer
Interventions
Magrolimab, Cetuximab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab in Patients With Solid Tumors

NCT04827576
View directory record Official record
Conditions
Solid Tumor
Interventions
Magrolimab, Docetaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Goodyear, Arizona • La Jolla, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

NCT05169944
View directory record Official record
Conditions
Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
Interventions
Magrolimab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

NCT05079230
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Magrolimab, Venetoclax, Azacitidine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
39
States / cities
Little Rock, Arkansas • Duarte, California • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1 Interventional Results available

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

NCT03248479
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Magrolimab, Azacitidine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
26
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Results available

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

NCT04599634
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions
Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

NCT04788043
View directory record Official record
Conditions
Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Magrolimab, Pembrolizumab, PET/CT
Drug · Procedure
Lead sponsor
Ranjana Advani
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

NCT03869190
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

NCT04313881
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Magrolimab, Azacitidine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Withdrawn Phase 1 Interventional

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

NCT05807126
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT03922477
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atezolizumab, Hu5F9-G4
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

NCT05330429
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Magrolimab, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT05835011
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Decitabine/Cedazuridine, Magrolimab
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

NCT03527147
View directory record Official record
Conditions
NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
AZD9150, Acalabrutinib, AZD6738, Hu5F9-G4, Rituximab, AZD5153
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Results available

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

NCT03558139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Magrolimab, Avelumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

NCT04892446
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Magrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04958785
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

NCT04854499
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

NCT04541017
View directory record Official record
Conditions
Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Mycosis Fungoides and Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magrolimab, Mogamulizumab, Positron Emission Tomography, Punch Biopsy
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

NCT04778410
View directory record Official record
Conditions
Myeloid Malignancies
Interventions
Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 17, 2026, 2:16 AM EDT